FDA Approves Bulevirtide as First Treatment for Chronic Hepatitis Delta Virus
- Food and Drug Administration (FDA) has approved Bulevirtide for the treatment of chronic Hepatitis Delta Virus (HDV), marking the first time a therapy has been authorized for this...
- The drug, identified as bulevirtide-gmod, is currently the first and only approved treatment available for chronic HDV infection.
- Gilead has secured the FDA authorization for the therapy, establishing a primary position in the market for hepatitis D treatments.
The U.S. Food and Drug Administration (FDA) has approved Bulevirtide for the treatment of chronic Hepatitis Delta Virus (HDV), marking the first time a therapy has been authorized for this condition.
The drug, identified as bulevirtide-gmod, is currently the first and only approved treatment available for chronic HDV infection.
Gilead has secured the FDA authorization for the therapy, establishing a primary position in the market for hepatitis D treatments.
The regulatory approval follows a period of development and review that included a previous rejection by the FDA approximately four years ago, according to reporting from Endpoints News.
The authorization provides a pharmacological option for a patient population that previously had no approved treatment for the chronic virus.